Shionogi to Acquire IntraBio for $2 Billion
Shionogi has agreed to acquire U.S.-based drugmaker IntraBio for $2 billion to strengthen its rare disease pipeline.
Shionogi has agreed to acquire Austin, Texas-based drugmaker IntraBio for $2 billion. The Japanese drugmaker said Monday that IntraBio’s expertise would strengthen Shionogi’s capabilities across its rare disease pipeline. Through the transaction, Shionogi would acquire global rights…